CYTOVIA Inc, IMMUNE Pharma's Oncology subsidiary, announces publication of results showing anti-metastatic properties of its lead drug Ceplene® and filing of a new worldwide patent
Additional potential in cancer immunotherapy with Ceplene in combination with Interleukin-15 (IL-15)
Immune Pharmaceuticals Inc. (NASDAQ; IMNP) a clinical stage biopharmaceutical company specializing in the development of novel targeted therapeutic agents in the fields of immuno-inflammation, dermatology and immuno-oncology, issued the following Letter to Shareholders.
Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company
Immune shareholders to receive additional pro rata shares in Cytovia
IMMUNE Pharmaceuticals' Oncology subsidiary, CYTOVIA, announces the filing of a world-wide patent protecting the use of Ceplene® in acute myeloid leukemia (AML) and other hematological cancers with mutated NPM1
Favorable relapse-free and overall survival in AML patients with persistent leukemic cells
Cytovia Inc, Immune Pharmaceuticals' Oncology Subsidiary, Enters into a Definitive Agreement with Pint Pharma for the Licensing and Commercialization of Ceplene® in Latin America
Cytovia Inc. ("Cytovia") the oncology subsidiary of Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune") announced today that it has entered into a licensing agreement with Pint Pharma International S.A. ("Pint") a pharmaceutical company focused on Latin America and other markets, for the marketing and distribution of Ceplene throughout Latin America (the "territory"). Pint Gmbh will separately enter into an investment agreement, which will lead to an investment of $4 million into Cytovia. Dr. Massimo Radaelli, Executive Chairman of Pint, will also join the board of Cytovia upon completion of the investment and effective spin off of Cytovia from Immune.
Immune Pharmaceuticals' Oncology Subsidiary, Cytovia, Announces Addl. Clinical Trial Results on the Efficacy of Ceplene® in Combination Low-Dose IL-2 in Patients With Acute Myeloid Leukemia, Recently Published in Leukemia, a Leading Hematology Journal
Sixty-seven per cent of patients with functional natural killer (NK) cells remained disease-free at a pre-determined end point that followed two years of treatment
Immune Pharmaceuticals' Oncology Subsidiary, Cytovia Inc. Provides Update to Proposed Pint Pharma Transaction: Substantial Agreement Reached on Material Terms of the Licensing and Commercialization of Ceplene® in Latin America
Immune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML)
Immune's subsidiary, CYTOVIA, to implement development and commercialization plan for Ceplene
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the "Company") announced today that on June 15, 2017, the Company received written notice from the Nasdaq that the Company has regained compliance with Listing Rule 5250(c)(1) and is in compliance with other applicable requirements required for listing on the Nasdaq. Accordingly, the Nasdaq has determined to continue the listing of the Company's securities.
Immune's subsidiary, Cytovia, plans commercialization activities in Europe and Latin America
Immune Pharmaceuticals Inc
Marknadsplats: First North
Interim Report Q2 2016